araag2/HINT huggingface dataset:
Clinical trial NCT02685618 (phase 2, status: completed)
Conditions: cardiac arrest
ICD codes: I97.120, I97.710, I46.9, P29.81, I46.2, I97.121, I97.711
Drugs: iloprost, saline
SMILES: [H][C@]12C[C@@H](O)[C@H](\C=C\[C@@H](O)CCCCC)[C@@]1([H])C\C(O2)=C\CCCC(O)=O, COCCC1=CC=C(OCC(O)CNC(C)C)C=C1
Eligibility criteria:

        Inclusion Criteria:

          1. Age ≥18 years

          2. OHCA of presumed cardiac cause

          3. Sustained ROSC*

          4. Unconsciousness (GCS <8) (patients not able to obey verbal commands) after sustained
             ROSC*

          5. Target temperature management is indicated.

        Exclusion Criteria:

          1. Conscious patients (obeying verbal commands)

          2. Females of childbearing potential (unless a negative human chorionic gonadotropin
             (HCG) test can rule out pregnancy within the inclusion window)

          3. Patients weighing more than 135kg

          4. In-hospital cardiac arrest (IHCA)

          5. OHCA of presumed non-cardiac cause, e.g. after trauma or dissection/rupture of major
             artery OR Cardiac arrest caused by initial hypoxia (i.e. drowning, suffocation,
             hanging).

          6. Known congenital bleeding diathesis (medically induced coagulopathy due to treatment
             with Vitamin K antagonists, Thrombininhibitors, Factor Xa inihbitors, ADP-receptor
             inhibitors, Aspirin, Asasantin, Persantin, NSAID, unfractionated and low molecular
             weight heparin does NOT exclude the patient).

          7. Suspected or confirmed acute intracranial bleeding

          8. Suspected or confirmed acute stroke

          9. Unwitnessed asystole

         10. Known limitations in therapy and Do Not Resuscitate-order

         11. Known disease making 180 days survival unlikely

         12. Known pre-arrest CPC 3 or 4

         13. >4 hours (240 minutes) from ROSC to screening

         14. Systolic blood pressure <80 mm Hg in spite of fluid loading/vasopressor and/or
             inotropic medication/intra-aortic balloon pump/axial flow device*

         15. Temperature on admission <30°C.

         16. Known allergy to Prostacyclin analogues
Clinical trial NCT02687542 (phase 2, status: terminated)
Conditions: parkinson disease
ICD codes: G20
Drugs: placebo, pf-06649751 low dose (1 mg qd), pf-06649751 middle dose 1 (3 mg qd), pf-06649751 middle dose 2 (7 mg qd), pf-06649751 high dose (15 mg qd)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    terminated 25sep17 due to insufficient efficacy. not due to safety reasons.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Females of non-childbearing potential and/or male subjects between the ages of 40 and
             85 years, inclusive.

          -  Clinical diagnosis of Parkinson's disease.

          -  Able to refrain from any Parkinson's disease medication not permitted by the protocol.

        Exclusion Criteria:

          -  Female of childbearing potential

          -  History or presence of atypical Parkinsonian syndrome.

          -  History of surgical intervention for Parkinson's disease.

          -  Severe acute or chronic medical or psychiatric condition or laboratory abnormality.

          -  Any condition possibly affecting drug absorption.

          -  Participation in other studies involving investigational drug(s), or treatment with
             any investigational drug within 30 days.
Clinical trial NCT02695810 (phase 2, status: completed)
Conditions: prediabetic state, obesity
ICD codes: E66.8, E66.9, E66.1, O99.214, O99.215, O99.210, O99.211
Drugs: dapagliflozin, metformin
SMILES: CN(C)C(=N)NC(N)=N, CSCC[C@H](N)C(O)=O
Eligibility criteria:

        Inclusion Criteria:

          -  HbA1c: from ≥5.7% (39 mmol/mol) to ≤6.4% (47 mmol/mol)

          -  Age: from ≥30 to ≤70 years of age

          -  BMI ≥25 kg/m2

        Exclusion Criteria:

          -  Uncontrolled medical issues including but not limited to cardiovascular pulmonary,
             rheumatologic, hematologic, oncologic, infectious, gastrointestinal or psychiatric
             disease; diabetes or other endocrine disease; immunosuppression;

          -  Current treatment with hormones which affect glucose metabolism;

          -  Current treatment with loop diuretics or thiazolidinediones;

          -  Current treatment with beta blockers or peroral steroids;

          -  Bariatric surgery within the past 2 years;

          -  Impaired renal function defined as an estimated GFR<60 ml/min/1.73m2;

          -  Neurogenic bladder disorders;

          -  Alcohol/drug abuse or in treatment with disulfiram (Antabus) at time of inclusion;

          -  Pregnant or lactating women;

          -  Fertile women not using birth control agents including oral contraceptives, gestagen
             injection, subdermal implants, hormonal vaginal ring, transdermal application, or
             intra-uterine devices;

          -  Allergic to one or more of the medications used in the study;

          -  Concomitant participation in other intervention study;

          -  Unable to understand the informed consent and the study procedures.
Clinical trial NCT02699450 (phase 2, status: completed)
Conditions: diabetic macular edema
ICD codes: E10.311, E10.319, E11.311, E11.319, E13.311, E13.319, E10.3513
Drugs: faricimab, ranibizumab
SMILES: CN\C(NCCSCC1=CC=C(CN(C)C)O1)=C/[N+]([O-])=O
Eligibility criteria:

        Inclusion Criteria:

          -  Macular edema associated with diabetic retinopathy

          -  Decreased visual acuity attributable primarily to DME

          -  Diagnosis of diabetes mellitus

        Exclusion Criteria:

          -  High risk proliferative diabetic retinopathy

          -  Cataract surgery within 3 months of Baseline, or any other previous intraocular
             surgery

          -  Uncontrolled glaucoma

          -  Current or history of ocular disease in the study eye other than DME

          -  Major illness or major surgical procedure within 1 month prior to Day 1

          -  Uncontrolled blood pressure

          -  Glycosylated hemoglobin (HbA1c) greater than (>) 12 percent (%) at screening

          -  Untreated diabetes mellitus or initiation of oral anti-diabetic medication or insulin
             within 4 months prior to Day 1
Clinical trial NCT02700568 (phase 2, status: completed)
Conditions: carcinoma, renal cell, clear cell renal cell carcinoma
ICD codes: C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8, C22.0, C4A.9, C7B.1, C4A.0, C4A.31, C4A.51, C4A.8
Drugs: axitinib
SMILES: [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H]
Eligibility criteria:

        Principle Inclusion Criteria:

          -  Histologic confirmation of Renal cell carcinoma with a clear cell component

          -  Patients must have measurable disease

          -  Previous treatment with sunitinib or pazopanib

          -  Favorable prognosis according to IMDC criteria

          -  Must have available tumor tissue for submission

          -  Subjects must also meet various laboratory parameters for inclusion

          -  Patients must give written informed consent prior to initiation of therapy

        Exclusion Criteria:

          -  Any underlying medical condition, which in the opinion of the Investigator, will make
             the administration of study drug hazardous or obscure the interpretation of adverse
             events

          -  Patients who have history of uncompensated diseases, metabolic dysfunction, physical
             examination finding, or clinical laboratory finding giving reasonable suspicion of a
             disease or condition that contraindicates the use of an investigational drug or that
             might affect the interpretation of the results of the study or render the subject at
             high risk from treatment complications.
Clinical trial NCT02700919 (phase 2, status: completed)
Conditions: pulmonary disease, chronic obstructive
ICD codes: J44.9, J44.1, J44.0
Drugs: bct197, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Male and female adults

          -  Presence of an active exacerbation of the ongoing COPD requiring hospitalization for
             treatment

          -  Subjects with a documented diagnosis of COPD C or D

          -  Current smokers or ex-smokers

          -  A documented history of at least one moderate or severe COPD exacerbation in the 12
             months preceding the Screening Visit that required antibiotics and/or systemic
             corticosteroid.

          -  Current regular treatment for COPD (for at least 2 months prior to the Screening
             Visit.

        Exclusion Criteria:

          -  Age less than 40 years old

          -  Current diagnosis of asthma

          -  Subjects who have already completed treatment for the current exacerbation of COPD

          -  Subjects currently requiring intensive care unit (ICU) and/or mechanical ventilation

          -  Received a course of PDE4, p38 or PDE3/4 inhibitors within their respective defined
             washout periods.
Clinical trial NCT02701764 (phase 2/phase 3, status: completed)
Conditions: dry eye
ICD codes: H04.121, H04.122, H04.123, H04.129, H35.3111, H35.3112, H35.3121
Drugs: pregabalin, placebo
SMILES: NCC1(CC(O)=O)CCCCC1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  18 and 65 years of age

          -  undergoing LASIK (unilateral or bilateral procedure).

          -  Females of child-bearing age will need a negative urine or serum pregnancy test at the
             screening visit.

          -  ocular and systemic medication regimen has been stable for 3 months

        Exclusion Criteria:

          -  Pregnant or lactating, participating in another study with an investigational drug
             within one month prior to screening

          -  Using gabapentin, pregabalin, anti-convulsants, duloxetine, venlafaxine (SNRI), or
             tri-cyclic antidepressants

          -  have a history of allergic, anaphylactic reaction, or severe systemic response to
             pregabalin or gabapentin

          -  use corticosteroids chronically or during the month prior to surgery, or have a
             history of corneal disease (HSV or varicella zoster keratitis, prior corneal incisions
             (cataract surgery, radial keratotomy, LASIK), prior corneal ulcer).

          -  patients with systemic co-morbidities that may confound DE such as HIV, sarcoidosis,
             graft-versus host disease or a collagen vascular disease.

          -  Adults unable to consent

          -  Individuals who are not yet adults (infants, children, teenagers)

          -  Prisoners
Clinical trial NCT02703415 (phase 2, status: completed)
Conditions: acute pain
ICD codes: G89.12, G89.18, G89.11, G89.3
Drugs: bupivacaine, tramadol
SMILES: CC1=CC(O)=CC(C)=C1Cl, COC1=CC=CC(=C1)[C@@]1(O)CCCC[C@@H]1CN(C)C
Eligibility criteria:

        Inclusion Criteria:

        lower abdominal operation

        Exclusion Criteria:

        Any systemic disease that might compromise the immune system severe coagulation disorder
        true allergy to local anesthetics patients with major malformations of the lower spine or
        meninges any cutaneous or subcutaneous lesion at the site of injection unplanned
        reoperation, or reoperation within three months Diabetes Melliutes
Clinical trial NCT02705625 (phase 2, status: completed)
Conditions: osteoarthritis, knee
ICD codes: M17.9, M17.0, M17.10, M17.11, M17.12, M17.2, M17.30
Drugs: miv-711, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Current average knee pain, defined as pain in either knee, within 1 week before visit
             1, for which the patient gives a severity score of ≥4, <10 on a 0-10 NRS (Numeric
             Rating Scale).

          -  Inclusive of 40-80 years old.

          -  Diagnosis of primary knee osteoarthritis

        Exclusion Criteria:

          -  The presence of any inflammatory arthritis

          -  Any generalized pain condition that may interfere with the evaluation of the target
             knee pain (e.g., fibromyalgia) as judged by the investigator.

          -  Any clinically severe or significant uncontrolled concurrent illness, which, in the
             opinion of the Investigator, would impair ability to give informed consent or take
             part in or complete this clinical study.

          -  Known or suspected intolerance or hypersensitivity to the investigational product,
             closely related compounds, or any of the stated ingredients.
Clinical trial NCT02708095 (phase 2, status: completed)
Conditions: systemic lupus erythematosus
ICD codes: M32.9, M32.0, M32.11, M32.12, M32.13, M32.14, M32.8
Drugs: baricitinib, placebo
SMILES: CCS(=O)(=O)N1CC(CC#N)(C1)N1C=C(C=N1)C1=C2C=CNC2=NC=N1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Have received a diagnosis of SLE at least 24 weeks prior to screening, meeting the
             American College of Rheumatology (ACR) 1982 revised criteria OR the 2012 Systemic
             Lupus Erythematosus International Collaborating Clinics (SLICC) criteria.

          -  Have a positive antinuclear antibody (ANA) (titer ≥1:80) and/or a positive
             anti-double-stranded deoxyribonucleic acid (dsDNA) as assessed by a central laboratory
             at screening.

          -  Have a SLEDAI-2K score ≥4 based on clinical symptoms (not including lab values) at
             randomization.

          -  Have active arthritis and/or active rash as defined by the SLEDAI-2K at randomization.

        Exclusion Criteria:

          -  Have active severe lupus nephritis.

          -  Have active severe central nervous system (CNS) lupus.

          -  Have a history or presence of cardiovascular, respiratory, hepatic, gastrointestinal,
             endocrine, hematological, neurological, or neuropsychiatric disorders or any other
             serious and/or unstable illness that, in the opinion of the investigator, could
             constitute an unacceptable risk when taking investigational product or interfere with
             the interpretation of data.

          -  Have a current or recent clinically serious viral, bacterial, fungal, or parasitic
             infection.

          -  Are currently receiving oral corticosteroids at doses >20-milligrams per day of
             prednisone (or equivalent) or have adjusted the dose of corticosteroids within 2 weeks
             of planned randomization.

          -  Have started treatment with or adjusted the dose of nonsteroidal anti-inflammatory
             drugs (NSAIDs) (for which the NSAID use is intended for treatment of signs and
             symptoms of SLE) within 4 weeks of planned randomization.

          -  Have started treatment with or adjusted the dose of an antimalarial within 12 weeks of
             planned randomization.

          -  Have started treatment with or adjusted the dose of an immunosuppressant within 12
             weeks of planned randomization.

          -  Have received cyclophosphamide (or any other cytotoxic agent) within 12 weeks prior to
             screening.
Clinical trial NCT02708186 (phase 2, status: completed)
Conditions: dementia with lewy bodies, rem sleep behavior disorder, parkinson's disease dementia
ICD codes: G31.83, G20
Drugs: nelotanserin, placebo
SMILES: COC1=CC=C(NC(=O)NC2=CC=C(F)C=C2F)C=C1C1=C(Br)C=NN1C, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Adult subjects at least 50 years of age, with a diagnosis of DLB or PDD and RBD based
             on Diagnostic and Statistical Manual of Mental Disorders Fifth Edition (DSM-5)
             diagnostic criteria

          -  Presence of frequent REM sleep behavior episodes

          -  Mini Mental State Examination score ≥ 18

        Exclusion Criteria:

          -  Subjects have a current diagnosis of significant psychotic disorders including, but
             not limited to, schizophrenia or bipolar disorder

          -  Subjects' RBD symptoms are secondary to or better accounted for by another medical
             condition, psychiatric disorder, or substance abuse

          -  Subjects with a current serious and/or unstable cardiovascular, respiratory, thyroid,
             gastrointestinal, renal, hematologic or other medical disorder
Clinical trial NCT02709109 (phase 2, status: completed)
Conditions: cystic fibrosis
ICD codes: E84.9, Z14.1, E84.0, E84.11, E84.8, E84.19, P09.4
Drugs: vx-371, saline, placebo, orkambi
SMILES: COCCC1=CC=C(OCC(O)CNC(C)C)C=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)(C)C1=CC(=C(O)C=C1NC(=O)C1=CNC2=CC=CC=C2C1=O)C(C)(C)C
Eligibility criteria:

        Inclusion Criteria:

          -  Willing and able to use the delivery device as directed by the study manual.

          -  Confirmed diagnosis of CF, defined as a sweat chloride value ≥60 mmol/L by
             quantitative pilocarpine iontophoresis.

          -  Homozygous for the F508del CFTR mutation. If the CFTR screening genotype result is not
             received before randomization, a previous CFTR genotype lab report may be used to
             establish eligibility.

          -  Percent predicted FEV1 of ≥40 to <90 percentage points adjusted for age, sex, and
             height according to the Global Lung Initiative (GLI) at the Screening Visit.

          -  Willing to discontinue physician-prescribed saline use.

          -  Female subjects of childbearing potential with a negative serum pregnancy test at the
             Screening Visit.

        Exclusion Criteria:

          -  History of any comorbidity, which in the opinion of the investigator, might confound
             the results of the study or pose an additional risk in administering study drug to the
             subject.

          -  Any clinically significant laboratory abnormalities at the Screening Visit that would
             interfere with the study assessments or pose an undue risk for the subject.

          -  An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in
             therapy (including antibiotics) for pulmonary disease within 28 days before Day 1
             (first dose of study drug).

          -  A 12 lead ECG demonstrating QTcF >450 msec at the Screening Visit.

          -  History of solid organ or hematological transplantation.

          -  Used diuretics or renin-angiotensin aldosterone system antihypertensive drugs in the
             28 days prior to Screening or an anticipated need for any of these medications during
             the study.

          -  Ongoing or prior participation in an investigational drug study within 30 days of the
             Screening Visit.

          -  Inability to withhold short-acting, long-acting, or once-daily, long-acting
             bronchodilator use for 4, 12, or 24 hours prior to clinic visit, respectively.

          -  History of significant intolerance to inhaled saline, or intolerance to the single
             dose of saline at Screening

          -  Known hypersensitivity or history of intolerance to Orkambi.

          -  Pregnant and nursing females.

          -  Subjects who have participated in Parion Sciences Study NCT02343445.
Clinical trial NCT02712008 (phase 2, status: completed)
Conditions: diabetic macular edema
ICD codes: E10.311, E10.319, E11.311, E11.319, E13.311, E13.319, E10.3513
Drugs: regn910-3, intravitreal aflibercept injection (iai)
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Key Inclusion Criteria:

          1. Men or women ≥18 years of age with type 1 or type 2 diabetes mellitus who have
             clinically significant DME with central involvement in the study eye

          2. BCVA ETDRS letter score of 73 to 24 (Snellen equivalent of 20/40 to 20/320) in the
             study eye

          3. Willing and able to comply with clinic visits and study-related procedures

          4. Provide signed informed consent

        Key Exclusion Criteria:

          1. Evidence of macular edema due to any cause other than diabetes mellitus in either eye

          2. IVT anti-VEGF in the study eye within 12 weeks of the screening visit

          3. Panretinal laser photocoagulation or macular laser photocoagulation in the study eye
             within 3 months of screening

        Note: Other inclusion/ exclusion criteria apply
Clinical trial NCT02712957 (phase 2, status: completed)
Conditions: pain, osteoarthritis of the knee
ICD codes: N50.82, R07.2, R07.82, R10.13, R10.33, R14.1, R52, M15.4, M15.0, M16.9, M17.9, M19.011, M19.012, M19.019
Drugs: neo6860, neo6860 placebo, naproxen, naproxen placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1, COC1=C(O)C=CC(CNC(=O)CCCC\C=C\C(C)C)=C1
Eligibility criteria:

        Inclusion Criteria:

          -  Body mass index (BMI) between 18.0 and 35.0 kg/m2 inclusive;

          -  Patients diagnosed with osteoarthritis of the knee, according to American College of
             Rheumatology (ACR) guidelines, by meeting at least 3 of the following: age > 50,
             morning stiffness < 30 minutes, crepitus on active motion, bone tenderness, bone
             enlargement, no palpable warmth of synovium;

          -  Grade I, II or III using Kellgren-Lawrence classification on an X-Ray of the knee

          -  WOMAC pain subscale ≥ 8

          -  R square of the Focused Analgesia Selection Task (FAST) outcome value greater than
             0.70

        Exclusion Criteria:

          -  Patients with, or with a history of, any clinically significant disorders (including
             fibromyalgia and other painful disorders) which may interfere with the primary
             objectives of the study

          -  Patients treated in the previous 3 months with topical capsaicin or intra-articular
             corticosteroids;

          -  Patients with a contra-indication for the use of Naproxen or acetaminophen;
Clinical trial NCT02713204 (phase 2, status: completed)
Conditions: neovascular age-related macular degeneration
ICD codes: H35.3211, H35.3212, H35.3221, H35.3222, H35.3231, H35.3232, H35.3291
Drugs: regn910-3, intravitreal aflibercept injection (iai)
SMILES: N[C@@H](CCCNC(N)=N)C(O)=O
Eligibility criteria:

        Key Inclusion Criteria:

          1. Men or women ≥50 years of age with active subfoveal CNV secondary to AMD, including
             juxtafoveal lesions that affect the fovea as evidenced by FA in the study eye as
             assessed by a central reading center

          2. BCVA ETDRS letter score of 73 to 24 (Snellen equivalent of 20/40 to 20/320) in the
             study eye.

          3. Willing and able to comply with clinic visits and study-related procedures.

          4. Provide signed informed consent.

        Key Exclusion Criteria:

          1. Evidence of CNV due to any cause other than AMD in either eye

          2. Prior IVT anti-VEGF in the study eye

          3. Evidence of DME or diabetic retinopathy (defined as more than 1 microaneurysm) in
             either eye in diabetic patients

          4. Any history of macular hole of stage 2 and above in the study eye